Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Mirabegron Extended-Release Tablets in the US
Details : Mirabegron is a beta-3 adrenergic receptor inhibitor approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.
Brand Name : Myrbetriq-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Launches Mirabegron Extended-release Tablets in the US
Details : Myrbetriq-Generic (mirabegron) is an FDA-approved beta-3 adrenergic receptor inhibitor for treating overactive bladder with urge incontinence and urinary urgency.
Brand Name : Myrbetriq-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2024
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Solifenacin Succinate,Mirabegron
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MSN Laboratories Gets CDSCO Panel Nod For FDCs Solifenacin, Mirabegron Capsules
Details : Solifenacin succinatei immediate release tablet is a muscarinic receptor antagonist and Mirabegron capsule is a potent and selective β3-adrenoceptor agonist, indicated for the treatment of overactive bladder.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2022
Lead Product(s) : Solifenacin Succinate,Mirabegron
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The U.S. Food and Drug Administration (FDA) approved Myrbetriq for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules for the treatment of NDO in pediatric patients aged three years and...
Brand Name : Myrbetriq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2021
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The NDA and sNDA were based on findings from a Phase 3 pivotal study that evaluated the efficacy, safety, tolerability and pharmacokinetics of mirabegron in children and adolescents with NDO and using clean intermittent catheterization.
Brand Name : Myrbetriq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2021
Lead Product(s) : Mirabegron
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?